secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0000012208-22-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed
--------------------------------------------------------------------------------

- Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.
- GAAP net loss $164.2M ($5.52 loss per diluted share) vs income $3,928M in Q3 2021, driven by Sartorius fair-value swings.
- Non-GAAP net income $77.9M ($2.60 diluted EPS) vs $112.2M ($3.71) in Q3 2021.
- Life Science segment sales $317.9M (-14.9% YoY); Clinical Diagnostics $361.9M (-2.8% YoY; +3.0% currency-neutral).
- FY22 guidance: non-GAAP currency-neutral revenue growth at high end of prior 1.0-2.0%; COVID revenue now ~$105M; operating margin ~19.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/0000012208-22-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/bio-20221027.htm
  HTML page:      https://secwatch.observer/filing/0000012208-22-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer